The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri… - The Lancet, 2022 - thelancet.com
Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

What's in a name? Renaming 'NAFLD'to 'MAFLD'

Y Fouad, I Waked, S Bollipo, A Gomaa… - Liver …, 2020 - Wiley Online Library
In medicine, language matters and the words used to name and describe a disease can
have a profound impact on patients and their families. Over the last two decades, many …

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update

CPG Panel, A Berzigotti, E Tsochatzis, J Boursier… - Journal of …, 2021 - Elsevier
Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

[HTML][HTML] Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention

F Tacke, R Weiskirchen - Annals of Translational Medicine, 2021 - ncbi.nlm.nih.gov
Liver fibrosis is the excessive expression and accumulation of extracellular matrix proteins in
the liver. Fibrotic scarring occurs as the consequence of chronic injury and inflammation …

Liver injury and the macrophage issue: molecular and mechanistic facts and their clinical relevance

S Roohani, F Tacke - International Journal of Molecular Sciences, 2021 - mdpi.com
The liver is an essential immunological organ due to its gatekeeper position to bypassing
antigens from the intestinal blood flow and microbial products from the intestinal …

The Lancet–EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities

MP Manns, P Burra, J Sargent, R Horton, TH Karlsen - The Lancet, 2018 - thelancet.com
Comment 622 www. thelancet. com Vol 392 August 25, 2018 populations. 1, 17 Viral
hepatitis B and D will, however, remain major challenges in terms of drug development and …

Identification of patients with advanced fibrosis due to nonalcoholic fatty liver disease: considerations for best practice

S Augustin, A Ahmed, N Alkhouri… - … and Liver Diseases, 2020 - discovery.ucl.ac.uk
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
prevalence has increased in the past two decades, resulting in a significant but under …

[PDF][PDF] The Lancet Commissions

B Petros - 2021 - hepatos.hr
Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

The EASL International Liver Foundation: A growing pup with missions that are distinct yet integrated with those of its mother

M Colombo, TH Karlsen - Journal of Hepatology, 2019 - journal-of-hepatology.eu
Since 2014, the Governing Board of the European Association for the Study of Liver (EASL)
has thoroughly explored the opportunities of setting up a foundation that could complement …

[PDF][PDF] Handling editor: Luca Valenti What's in a name? Renaming “NAFLD''to “MAFLD”.

YM FOUAD, DRD ATTIA - researchgate.net
It has been nearly four decades since Susan Sontag brought to attention the metaphorical
meanings of illness and the consequences of these meanings for the ways that illness is …